Johnson & Johnson ($JNJ) was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled, newly unsealed court documents show. Report | Report (sub. req.)
Undertaking commercialization strategy and planning from early stages of development can ensure that considerable R&D investment results in successful market and patient access. Join HERON, a PAREXEL Company, in a timely webinar that addresses best practice commercialization planning. Register to watch now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!